KROS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.66M

+20.4%

-0.438

-61.55%

616.25K

-99.71%

-0.590

-116.3%

622.50K

-96.57%

-0.630

-17.11%

Estimates Revision

The market is revising Downward the revenue expectations for Keros Therapeutics, Inc. (KROS) for FY2025, with the revenue forecasts being adjusted by -2.23% over the past three months. During the same period, the stock price has changed by 19.11%.

Revenue Estimates for FY2025

Revise Downward

-2.23%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+131.55%

In Past 3 Month

Stock Price

Go Up

+19.11%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast KROS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KROS is 20.80 USD with a low forecast of 16.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

16.00

Averages

20.80

High

27.00

Current: 0.000

Low

16.00

Averages

20.80

High

27.00

BofA

Jason Zemansky

Neutral

maintain

$18 -> $19

2025-11-28

Reason

BofA

Jason Zemansky

Price Target

$18 -> $19

2025-11-28

maintain

Neutral

Reason

BofA analyst Jason Zemansky raised the firm's price target on Keros Therapeutics to $19 from $18 and keeps a Neutral rating on the shares after adjusting projections following the company's Q3 earnings update.

Oppenheimer

Andreas Argyrides

Outperform

maintain

$23 -> $27

2025-11-12

Reason

Oppenheimer

Andreas Argyrides

Price Target

$23 -> $27

2025-11-12

maintain

Outperform

Reason

Oppenheimer analyst Andreas Argyrides raised the firm's price target on Keros Therapeutics to $27 from $23 and keeps an Outperform rating on the shares following quarterly results and business update. The firm continues to anticipate the Phase 2 trial initiation for KER-065/DMD in Q1 2026, and is encouraged by recent additional Phase 1 data demonstrating continued durability and safe profile. As such, Oppenheimer sees KER-065 as a potentially differentiated TGF-beta inhibitor by avoiding BMP9/10 binding with no SAEs, and sees broader potential across other bone disorders.

Oppenheimer

Andreas Argyrides

Outperform

maintain

$23 -> $27

2025-11-07

Reason

Oppenheimer

Andreas Argyrides

Price Target

$23 -> $27

2025-11-07

maintain

Outperform

Reason

Oppenheimer analyst Andreas Argyrides raised the firm's price target on Keros Therapeutics to $27 from $23 and keeps an Outperform rating on the shares following quarterly results. The firm continues to anticipate the Phase 2 trial initiation for KER-065/DMD in Q1 2026, and is encouraged by recent additional Phase 1 data demonstrating continued durability and safe profile. As such, Oppenheimer sees KER-065 as a potentially differentiated TGF-beta inhibitor by avoiding BMP9/10 binding with no SAEs, and see broader potential across other bone disorders.

BofA

Jason Zemansky

Buy -> Neutral

downgrade

$32 -> $18

2025-06-10

Reason

BofA

Jason Zemansky

Price Target

$32 -> $18

2025-06-10

downgrade

Buy -> Neutral

Reason

BofA analyst Jason Zemansky downgraded Keros Therapeutics to Neutral from Buy with a price target of $18, down from $32. The company announced the conclusion of its strategic review, with the board opting to move forward with KER-065 for Duchenne muscular dystrophy and to return $375M in excess capital to shareholders, the analyst tells investors in a research note. The firm says the downgrade isn't an indictment of what it still thinks "is an intriguing" platform an pipeline. However, even acknowledging the stock's relative valuation and "downside protection" from its strong cash position, BofA suspects near-term share upside may be limited with key insights on 'KER-065 unlikely for some time and safety still an overhang. Investors will likely require more to re-engage at this point, contends the firm.

BofA

Jason Zemansky

Buy

maintain

$33 -> $32

2025-05-27

Reason

BofA

Jason Zemansky

Price Target

$33 -> $32

2025-05-27

maintain

Buy

Reason

BofA analyst Jason Zemansky lowered the firm's price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares. The firm notes frustrations from bulls, with shares trading absent much value for the Takeda (TAK) deal, but whether cibotercept and KER-065 are meaningful drags on sentiment or the P&L, as argued by activist ADAR1 Capital Management, is "less clear to us," the analyst tells investors.

Scotiabank

Outperform

NULL

downgrade

$41 -> $26

2025-05-12

Reason

Scotiabank

Price Target

$41 -> $26

2025-05-12

downgrade

Outperform

NULL

Reason

Scotiabank lowered the firm's price target on Keros Therapeutics to $26 from $41 and keeps an Outperform rating on the shares. The firm is updating its price targets on biotechnology stocks following Q1 results, the analyst tells investors. The firm sees limited value-driving catalysts for the stock in the near-term.

Valuation Metrics

The current forward P/E ratio for Keros Therapeutics Inc (KROS.O) is -9.44, compared to its 5-year average forward P/E of -9.77. For a more detailed relative valuation and DCF analysis to assess Keros Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.77

Current PE

-9.44

Overvalued PE

-5.16

Undervalued PE

-14.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.40

Current EV/EBITDA

2.66

Overvalued EV/EBITDA

1.56

Undervalued EV/EBITDA

-6.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

17258.99

Current PS

102.14

Overvalued PS

87279.28

Undervalued PS

-52761.30

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KROS News & Events

Events Timeline

No data

News

2.0

01-02NASDAQ.COM

Five Low Price-to-Book Stocks to Buy: AES, BorgWarner, Enersys, PG&E, Keros

6.5

2025-12-16NASDAQ.COM

Zacks.com Spotlights StoneCo, General Motors, Enersys, Deutsche, and Keros

3.0

2025-12-12NASDAQ.COM

Reasons to Consider Keros Therapeutics, Inc. (KROS) as a Strong Momentum Stock: Is It Time to Buy?

People Also Watch

Frequently Asked Questions

What is Keros Therapeutics Inc (KROS) stock price today?

The current price of KROS is 19.2 USD — it has increased 3.34 % in the last trading day.

What is Keros Therapeutics Inc (KROS)'s business?

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

What is the price predicton of KROS Stock?

What is Keros Therapeutics Inc (KROS)'s revenue for the last quarter?

Keros Therapeutics Inc revenue for the last quarter amounts to 14.26M USD, increased 3575.77 % YoY.

What is Keros Therapeutics Inc (KROS)'s earnings per share (EPS) for the last quarter?

Keros Therapeutics Inc. EPS for the last quarter amounts to -0.18 USD, decreased -87.23 % YoY.

What changes have occurred in the market's expectations for Keros Therapeutics Inc (KROS)'s fundamentals?

How many employees does Keros Therapeutics Inc (KROS). have?

Keros Therapeutics Inc (KROS) has 169 emplpoyees as of January 10 2026.

What is Keros Therapeutics Inc (KROS) market cap?

Today KROS has the market capitalization of 584.95M USD.